Management of drug resistantTB in patients with HIV co-infection

Emanuele Pontali, Giovanni Sotgiu, Rosella Centis, Lia Dambrosio, Antonio Spanevello, Giovanni Battista Migliori

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction: Multidrug-resistant and extensively drug-resistant tuberculosis (MDR- and XDR-TB) are major public health concerns worldwide. Their association with HIV/AIDS infection has contributed to the slowing down of TB incidence decline over the last two decades, therefore representing one of the most important barriers to reach TB elimination. Areas covered: The aim of this manuscript is to critically review the recent scientific evidence on the management of drug-resistant TB (essentially MDR- and XDR-TB) in subjects coinfected with HIV, focusing on the two new recently-approved anti-TB drugs delamanid and bedaquiline. The medical search-engine PubMed was used, selecting the time-period January 2013 - February 2015, and using the following Keywords: drug-resistant TB, multidrug resistant TB (or MDR-TB), extensively drug-resistant TB (or XDR-TB), delamanid and bedaquiline. Expert opinion: The TB/HIV co-epidemic can be faced by implementing the 12 TB/HIV collaborative activities recommended by the World Health Organization. They are focused on the systematic screening of individuals to detect the Mycobacterium tuberculosis infection in HIV-positives, as well as HIV infection in TB patients in order to ensure a rapid initiation of the anti-retroviral therapy (ART). The clinical and public health management of HIV-positive individuals with MDR-TB is complex and expensive, given the cost of second line anti-TB drugs (including the new drugs, delamanid and bedaquiline) and ART. Political commitment and more investment to identify shorter, cheaper and effective anti-TB and HIV regimens as well as better diagnostics and, hopefully, a vaccine will contribute to boost the efforts to eliminate TB.

Original languageEnglish
Pages (from-to)2737-2750
Number of pages14
JournalExpert Opinion on Pharmacotherapy
Volume16
Issue number18
DOIs
Publication statusPublished - Dec 12 2015

Fingerprint

Coinfection
bedaquiline
HIV Infections
Extensively Drug-Resistant Tuberculosis
HIV
Pharmaceutical Preparations
Public Health
Search Engine
Mycobacterium Infections
Expert Testimony
Mycobacterium tuberculosis
PubMed
Acquired Immunodeficiency Syndrome
Vaccines
Costs and Cost Analysis
Incidence
Therapeutics
OPC-67683

Keywords

  • bedaquiline
  • delamanid
  • HIV
  • MDR-TB
  • prevention
  • tuberculosis
  • XDR-TB

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Management of drug resistantTB in patients with HIV co-infection. / Pontali, Emanuele; Sotgiu, Giovanni; Centis, Rosella; Dambrosio, Lia; Spanevello, Antonio; Migliori, Giovanni Battista.

In: Expert Opinion on Pharmacotherapy, Vol. 16, No. 18, 12.12.2015, p. 2737-2750.

Research output: Contribution to journalArticle

@article{61a6c3a1a71243c69a525efdadca5503,
title = "Management of drug resistantTB in patients with HIV co-infection",
abstract = "Introduction: Multidrug-resistant and extensively drug-resistant tuberculosis (MDR- and XDR-TB) are major public health concerns worldwide. Their association with HIV/AIDS infection has contributed to the slowing down of TB incidence decline over the last two decades, therefore representing one of the most important barriers to reach TB elimination. Areas covered: The aim of this manuscript is to critically review the recent scientific evidence on the management of drug-resistant TB (essentially MDR- and XDR-TB) in subjects coinfected with HIV, focusing on the two new recently-approved anti-TB drugs delamanid and bedaquiline. The medical search-engine PubMed was used, selecting the time-period January 2013 - February 2015, and using the following Keywords: drug-resistant TB, multidrug resistant TB (or MDR-TB), extensively drug-resistant TB (or XDR-TB), delamanid and bedaquiline. Expert opinion: The TB/HIV co-epidemic can be faced by implementing the 12 TB/HIV collaborative activities recommended by the World Health Organization. They are focused on the systematic screening of individuals to detect the Mycobacterium tuberculosis infection in HIV-positives, as well as HIV infection in TB patients in order to ensure a rapid initiation of the anti-retroviral therapy (ART). The clinical and public health management of HIV-positive individuals with MDR-TB is complex and expensive, given the cost of second line anti-TB drugs (including the new drugs, delamanid and bedaquiline) and ART. Political commitment and more investment to identify shorter, cheaper and effective anti-TB and HIV regimens as well as better diagnostics and, hopefully, a vaccine will contribute to boost the efforts to eliminate TB.",
keywords = "bedaquiline, delamanid, HIV, MDR-TB, prevention, tuberculosis, XDR-TB",
author = "Emanuele Pontali and Giovanni Sotgiu and Rosella Centis and Lia Dambrosio and Antonio Spanevello and Migliori, {Giovanni Battista}",
year = "2015",
month = "12",
day = "12",
doi = "10.1517/14656566.2015.1100169",
language = "English",
volume = "16",
pages = "2737--2750",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "18",

}

TY - JOUR

T1 - Management of drug resistantTB in patients with HIV co-infection

AU - Pontali, Emanuele

AU - Sotgiu, Giovanni

AU - Centis, Rosella

AU - Dambrosio, Lia

AU - Spanevello, Antonio

AU - Migliori, Giovanni Battista

PY - 2015/12/12

Y1 - 2015/12/12

N2 - Introduction: Multidrug-resistant and extensively drug-resistant tuberculosis (MDR- and XDR-TB) are major public health concerns worldwide. Their association with HIV/AIDS infection has contributed to the slowing down of TB incidence decline over the last two decades, therefore representing one of the most important barriers to reach TB elimination. Areas covered: The aim of this manuscript is to critically review the recent scientific evidence on the management of drug-resistant TB (essentially MDR- and XDR-TB) in subjects coinfected with HIV, focusing on the two new recently-approved anti-TB drugs delamanid and bedaquiline. The medical search-engine PubMed was used, selecting the time-period January 2013 - February 2015, and using the following Keywords: drug-resistant TB, multidrug resistant TB (or MDR-TB), extensively drug-resistant TB (or XDR-TB), delamanid and bedaquiline. Expert opinion: The TB/HIV co-epidemic can be faced by implementing the 12 TB/HIV collaborative activities recommended by the World Health Organization. They are focused on the systematic screening of individuals to detect the Mycobacterium tuberculosis infection in HIV-positives, as well as HIV infection in TB patients in order to ensure a rapid initiation of the anti-retroviral therapy (ART). The clinical and public health management of HIV-positive individuals with MDR-TB is complex and expensive, given the cost of second line anti-TB drugs (including the new drugs, delamanid and bedaquiline) and ART. Political commitment and more investment to identify shorter, cheaper and effective anti-TB and HIV regimens as well as better diagnostics and, hopefully, a vaccine will contribute to boost the efforts to eliminate TB.

AB - Introduction: Multidrug-resistant and extensively drug-resistant tuberculosis (MDR- and XDR-TB) are major public health concerns worldwide. Their association with HIV/AIDS infection has contributed to the slowing down of TB incidence decline over the last two decades, therefore representing one of the most important barriers to reach TB elimination. Areas covered: The aim of this manuscript is to critically review the recent scientific evidence on the management of drug-resistant TB (essentially MDR- and XDR-TB) in subjects coinfected with HIV, focusing on the two new recently-approved anti-TB drugs delamanid and bedaquiline. The medical search-engine PubMed was used, selecting the time-period January 2013 - February 2015, and using the following Keywords: drug-resistant TB, multidrug resistant TB (or MDR-TB), extensively drug-resistant TB (or XDR-TB), delamanid and bedaquiline. Expert opinion: The TB/HIV co-epidemic can be faced by implementing the 12 TB/HIV collaborative activities recommended by the World Health Organization. They are focused on the systematic screening of individuals to detect the Mycobacterium tuberculosis infection in HIV-positives, as well as HIV infection in TB patients in order to ensure a rapid initiation of the anti-retroviral therapy (ART). The clinical and public health management of HIV-positive individuals with MDR-TB is complex and expensive, given the cost of second line anti-TB drugs (including the new drugs, delamanid and bedaquiline) and ART. Political commitment and more investment to identify shorter, cheaper and effective anti-TB and HIV regimens as well as better diagnostics and, hopefully, a vaccine will contribute to boost the efforts to eliminate TB.

KW - bedaquiline

KW - delamanid

KW - HIV

KW - MDR-TB

KW - prevention

KW - tuberculosis

KW - XDR-TB

UR - http://www.scopus.com/inward/record.url?scp=84952716424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952716424&partnerID=8YFLogxK

U2 - 10.1517/14656566.2015.1100169

DO - 10.1517/14656566.2015.1100169

M3 - Article

VL - 16

SP - 2737

EP - 2750

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 18

ER -